Comprehensive medication guide to Myrbetriq including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$30 copay for generic mirabegron on Tier 1–2 plans; brand Myrbetriq may be Tier 3–4 with higher copay or require step therapy and prior authorization.
Estimated Cash Pricing
$457–$625 retail for brand Myrbetriq; generic mirabegron ER available as low as $117–$189 with GoodRx or SingleCare coupons for a 30-day supply.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Myrbetriq is the brand name for mirabegron, an extended-release tablet manufactured by Astellas Pharma US, Inc. It was first approved by the FDA in 2012 for the treatment of overactive bladder (OAB) in adults, and later expanded in 2021 to include pediatric patients with neurogenic detrusor overactivity (NDO). A generic version of mirabegron extended-release became available in the U.S. market beginning in early 2024.
Myrbetriq belongs to a drug class called beta-3 adrenergic agonists. Unlike most other OAB medications — which are anticholinergics that block nerve receptors throughout the body — Myrbetriq works by activating beta-3 receptors specifically in the bladder muscle, promoting relaxation and increasing bladder capacity. This targeted mechanism results in fewer systemic side effects such as dry mouth and constipation.
Myrbetriq comes in 25 mg and 50 mg extended-release tablets, as well as an 8 mg/mL granule formulation for pediatric oral suspension. It is taken once daily and is not a controlled substance, meaning it can be prescribed by any licensed healthcare provider including through telehealth.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Myrbetriq (mirabegron) is a selective beta-3 adrenergic receptor agonist. The bladder wall contains smooth muscle — the detrusor muscle — which is richly populated with beta-3 adrenergic receptors. In overactive bladder, the detrusor muscle contracts prematurely and involuntarily before the bladder is full, creating sudden, strong urges to urinate.
Myrbetriq works by stimulating these beta-3 receptors during the bladder filling phase. This stimulation activates a signaling cascade that increases intracellular cyclic AMP (cAMP), which causes the detrusor muscle to relax. A more relaxed detrusor can hold more urine before triggering urgency signals, reducing the frequency of urination and urgency episodes.
Importantly, Myrbetriq does not block the contraction signal during voiding, so normal bladder emptying is preserved. Because beta-3 receptors are concentrated primarily in the bladder, Myrbetriq avoids the body-wide anticholinergic side effects — dry mouth, constipation, blurred vision, cognitive effects — that occur with older OAB drugs that target muscarinic receptors throughout the body.
25 mg — extended-release tablet
Starting dose for adults; take once daily with water, swallow whole
50 mg — extended-release tablet
Maintenance dose; may increase to this after 4-8 weeks at 25 mg if symptoms not controlled
8 mg/mL — granules for oral suspension (pediatric)
Weight-based dosing for pediatric patients with NDO; take with food; not interchangeable with tablets on mg-per-mg basis
As of 2026, Myrbetriq is not on the FDA's official drug shortage list. Brand-name Myrbetriq from Astellas is generally available, though stock varies by pharmacy. The more significant access issue involves generic mirabegron: patent litigation resulted in a federal court blocking manufacturers Lupin and Zydus from selling their generic versions in April 2025. Other manufacturers like Alkem remain in the market, but pharmacy-level stock is inconsistent depending on which supplier each pharmacy uses.
Additionally, major insurance plans including UnitedHealthcare implemented step therapy requirements for mirabegron (effective November 2025), requiring patients to fail two alternative OAB medications before coverage kicks in. This creates access delays for patients on affected plans.
If you're having trouble finding Myrbetriq at your pharmacy, medfinder is a paid service that calls local pharmacies on your behalf to locate which ones have your medication in stock, then texts you the results. It's especially useful for navigating the inconsistent availability caused by Myrbetriq's evolving generic market.
Myrbetriq is not a controlled substance, so there are no DEA scheduling restrictions on who can prescribe it. Any licensed prescriber can write a Myrbetriq prescription without special registration or restrictions. Prescribers who commonly manage overactive bladder and prescribe Myrbetriq include:
Because Myrbetriq is not a controlled substance, it is widely available via telehealth. Many online urology and primary care telehealth platforms can evaluate OAB symptoms and issue Myrbetriq prescriptions after a virtual visit. For uncomplicated OAB in adults, a telehealth prescription is fully appropriate. Patients with blood in urine, pelvic pain, or incomplete bladder emptying should seek in-person evaluation first.
No. Myrbetriq (mirabegron) is not a controlled substance and is not scheduled by the DEA under the Controlled Substances Act. It has no recognized abuse potential or addiction risk.
Because Myrbetriq is not controlled, there are no special prescribing restrictions. Any licensed healthcare provider — including primary care physicians, urologists, OB-GYNs, nurse practitioners, physician assistants, and telehealth providers — can prescribe it without DEA registration requirements for controlled substances. Prescriptions can be called in, faxed, e-prescribed, or prescribed remotely via telehealth. Refills are also unrestricted from a scheduling standpoint, though your insurance plan may have quantity or refill limits.
Most patients tolerate Myrbetriq well. Common side effects (occurring in >2% of patients in clinical trials) include:
Serious side effects requiring immediate medical attention:
Know what you need? Skip the search.
Vibegron (Gemtesa)
Also a beta-3 adrenergic agonist — same mechanism as Myrbetriq. One 75 mg tablet daily; brand-name only (~$692 retail); may be covered when Myrbetriq isn't, or vice versa.
Oxybutynin (generic)
Inexpensive anticholinergic OAB drug (~$5-10/month generic). More side effects (dry mouth, constipation, cognitive effects in elderly) but widely available and effective.
Solifenacin (Vesicare)
Antimuscarinic; more bladder-selective than oxybutynin; can be combined with Myrbetriq for greater efficacy. Generic available at lower cost than brand.
Tolterodine (Detrol)
Antimuscarinic available as IR and ER formulations; generic available; well-tolerated compared to oxybutynin; does not raise blood pressure like Myrbetriq.
Prefer Myrbetriq? We can find it.
Ozanimod (Zeposia)
majorAVOID: Concurrent use can cause hypertensive crisis. Ozanimod's active metabolite inhibits MAO-B; combining with CYP2D6-affecting drugs increases norepinephrine risk.
Digoxin
moderateStart with lowest digoxin dose; monitor serum digoxin concentrations and titrate to clinical effect. Myrbetriq increases digoxin exposure via P-glycoprotein interaction.
Metoprolol
moderateMyrbetriq inhibits CYP2D6, which metabolizes metoprolol. May increase metoprolol blood levels, causing bradycardia or excessive BP lowering. Monitor heart rate and BP.
Flecainide / Propafenone
moderateNarrow therapeutic index antiarrhythmics metabolized by CYP2D6. Myrbetriq may increase levels — monitor for arrhythmia or toxicity.
Warfarin
minorPostmarketing reports of increased INR when taken with mirabegron. Monitor INR when starting or stopping Myrbetriq in patients on warfarin.
Myrbetriq (mirabegron) is one of the most important advances in overactive bladder treatment in recent decades. Its beta-3 adrenergic mechanism delivers effective OAB symptom control without the anticholinergic side effects — dry mouth, constipation, cognitive effects — that cause so many patients to abandon older OAB medications. It is particularly valuable for elderly patients and those with multiple comorbidities where anticholinergic burden is a clinical concern.
Access challenges in 2026 are real but manageable. Generic mirabegron supply varies due to ongoing patent litigation, and insurance step therapy requirements have added complexity for some patients. But with the right combination of savings programs (Astellas Momentum Savings Card, Patient Assistance Program, GoodRx coupons for generic), most patients can access Myrbetriq at a manageable cost.
If you're struggling to fill your Myrbetriq prescription at your local pharmacy, medfinder is a paid service that calls pharmacies in your area to find which ones currently have Myrbetriq in stock, then texts you the results — saving you time and frustration.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini